Additionally, our finding that S. aureus osteomyelitis patients never develop neutralizing anti-Gmd antibodies (Group 2) or develop them too late in the disease process (Group 4) indirectly supports our hypothesis of anti-Gmd mAb therapy. This evidence concerns the gene GMDS and osteomyelitis.